214 related articles for article (PubMed ID: 16111460)
1. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
Ng R; Green MD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):585-90. PubMed ID: 16111460
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim use during chemotherapy: current and future applications.
Wolf T; Densmore JJ
Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
[TBL] [Abstract][Full Text] [Related]
6. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Waladkhani AR
Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
8. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
Lyman GH; Lalla A; Barron RL; Dubois RW
Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim for chemotherapy-induced neutropenia.
Bedell C
Clin J Oncol Nurs; 2003; 7(1):55-6, 63-4. PubMed ID: 12629935
[TBL] [Abstract][Full Text] [Related]
13. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
Siena S; Piccart MJ; Holmes FA; Glaspy J; Hackett J; Renwick JJ
Oncol Rep; 2003; 10(3):715-24. PubMed ID: 12684649
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
15. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
Ricotta R; Cerea G; Schiavetto I; Maugeri MR; Pedrazzoli P; Siena S
Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
[TBL] [Abstract][Full Text] [Related]
17. A comparison of pegfilgrastim and filgrastim.
Grigg AP
Clin Adv Hematol Oncol; 2005 Mar; 3(3):176, 179-80. PubMed ID: 16166989
[No Abstract] [Full Text] [Related]
18. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil growth factors.
Crawford J
Curr Hematol Rep; 2002 Nov; 1(2):95-102. PubMed ID: 12901130
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies.
Fritsch P; Schwinger W; Schwantzer G; Lackner H; Sovinz P; Wendelin G; Benesch M; Sipurzynski S; Urban C
Pediatr Blood Cancer; 2010 Jan; 54(1):134-7. PubMed ID: 19785023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
